A Novel Therapeutic Targeting the tPA-NMDAr Interaction for Parkinson’s Disease
Objective: Glunomab, a monoclonal antibody designed to inhibit the interaction between tissue plasminogen activator (tPA) and the N-methyl-D-aspartate receptor (NMDAr), has demonstrated therapeutic potential across…Organoid-Based AI Clinical Trial Platform for Phase 0 Studies in Parkinson’s Disease
Objective: we developed an organoid-based AI-driven platform to classify patient specific molecular subtypes and predict drug efficacy through an AI-powered validation pipeline. Patient-derived induced pluripotent…Analyzing Longitudinal Correlation Between CSF Tau, Alpha-Synuclein, and Dysautonomia in Parkinson’s Disease Over Five Years
Objective: To examine the longitudinal association between tau, alpha-synuclein, and dysautonomia in Parkinson’s disease (PD). Background: PD is characterized by dopaminergic neural loss [1] and…Elucidating Tau and Alpha-synuclein Co-pathology in RAB39b X-linked Parkinson’s Disease.
Objective: Elucidate the mechanisms underlying pathogenesis of X-linked Parkinson’s disease (PD) due to the RAB39B p.G192R mutation. Background: RAB39B p.G192R causes X-linked PD with decreased…Gene-Caffeine Interaction in Parkinson’s Disease: A Case-Control Study of Alpha-synuclein SNPs
Objective: Investigating the interaction between genetic susceptibility and caffeine intake in modulating Parkinson’s disease (PD) risk. Background: PD arises from a complex interplay of genetic…Cutaneous Phosphorylated Alpha-Synuclein Deposition in Multiple System Atrophy
Objective: To report differences in the amount, localization and topographic distribution of cutaneous P-SYN deposition between cerebellar and parkinsonian variants of MSA. Background: MSA is…Results From a Dose-Blinded, Phase II Extension Study Evaluating Long-Term Efficacy, Safety and Tolerability of Minzasolmin in Participants With Parkinson’s Disease
Objective: ORCHESTRA XT (PD0055; NCT05543252) was a Phase II, dose-blinded extension of the ORCHESTRA Phase II, proof-of-concept study (NCT04658186). ORCHESTRA XT assessed the pharmacodynamic effects of…Serum based estimations of CFAH, Gelsolin, CNDP1 and DKK3 levels suggest involvement of multiple pathways in pathogenesis of Parkinson’s disease.
Objective: To estimate levels of complement factor H (CFAH), phosphorylated alpha-syn (p- a-syn), gelsolin, carnosine dipeptidase-1 (CNDP1) and DKK3 in serum of Parkinson’s disease (PD) patients…Salivary Biomarkers in Parkinson’s Disease: A Follow-Up Study
Objective: Investigate longitudinal changes in salivary levels of oligomeric and total a-synuclein (a-syn), phosphorylated-tau (p-tau), total tau, MAP-LC3, and TNFa in Parkinson’s Disease (PD) patientsAssess…α-Synuclein Triggers Neuroinflammatory Damage through the suppression of MEF2C
Objective: To explore the effects of microglial myocyte enhancer factor 2C (MEF2C) in neuroinflammation induced by α-synuclein. Background: The abnormal aggregation of α-synuclein (α-syn) is a critical…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 60
- Next Page »